NLRP3 inflammasome as a therapeutic target in doxorubicin-induced cardiotoxicity: role of phytochemicals
- PMID: 40313623
- PMCID: PMC12043718
- DOI: 10.3389/fphar.2025.1567312
NLRP3 inflammasome as a therapeutic target in doxorubicin-induced cardiotoxicity: role of phytochemicals
Abstract
Doxorubicin (DOX) has received widespread attention as a broad-spectrum antitumor drug. However, it has been a recognized challenge that long-term DOX injections can lead to severe cardiotoxicity. There are numerous interventions to DOX-induced cardiotoxicity, and the most cost-effective is phytochemicals. It has been reported that phytochemicals have complex and diverse biological properties, facilitating the mitigation of DOX-induced cardiotoxicity. DOX-induced cardiotoxicity has numerous pathological mechanisms, and the nod-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome-mediated cardiomyocyte pyroptosis is one of them. This review initially presents an overview of the pathological mechanisms that underlie cardiotoxicity induced by DOX. Subsequently, we present a comprehensive elucidation of the structure and activation of the NLRP3 inflammasome. Finally, we provide a detailed summary of phytochemicals that can mitigate DOX-induced cardiotoxicity by influencing the expression of the NLRP3 inflammasome in cardiomyocytes.
Keywords: DOX-induced cardiotoxicity; NLRP3 inflammasome; myocardial injury; phytochemicals; pyroptosis.
Copyright © 2025 Zhao, Duan, Zhao, Lv, Tian, Yang and Dong.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Involvement of ROS/NLRP3 Inflammasome Signaling Pathway in Doxorubicin-Induced Cardiotoxicity.Cardiovasc Toxicol. 2020 Oct;20(5):507-519. doi: 10.1007/s12012-020-09576-4. Cardiovasc Toxicol. 2020. PMID: 32607760
-
Trastuzumab potentiates doxorubicin-induced cardiotoxicity via activating the NLRP3 inflammasome in vivo and in vitro.Biochem Pharmacol. 2023 Aug;214:115662. doi: 10.1016/j.bcp.2023.115662. Epub 2023 Jun 16. Biochem Pharmacol. 2023. PMID: 37331637
-
Amentoflavone mitigates doxorubicin-induced cardiotoxicity by suppressing cardiomyocyte pyroptosis and inflammation through inhibition of the STING/NLRP3 signalling pathway.Phytomedicine. 2023 Aug;117:154922. doi: 10.1016/j.phymed.2023.154922. Epub 2023 Jun 10. Phytomedicine. 2023. PMID: 37321078
-
The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin.Arch Toxicol. 2021 Jan;95(1):1-9. doi: 10.1007/s00204-020-02876-2. Epub 2020 Aug 27. Arch Toxicol. 2021. PMID: 32852568 Review.
-
Targeting the NLRP3 by Natural Compounds: Therapeutic Strategies to Mitigate Doxorubicin-Induced Cardiotoxicity.Cell Biochem Biophys. 2025 Mar 18. doi: 10.1007/s12013-025-01723-4. Online ahead of print. Cell Biochem Biophys. 2025. PMID: 40100343 Review.
Cited by
-
Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update.J Cardiovasc Dev Dis. 2025 May 30;12(6):207. doi: 10.3390/jcdd12060207. J Cardiovasc Dev Dis. 2025. PMID: 40558642 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources